Research programme: cancer therapeutics - Nektar Therapeutics

Drug Profile

Research programme: cancer therapeutics - Nektar Therapeutics

Alternative Names: NKTR 262; NKTR-218; NKTR-255

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Class Interleukins; Macromolecular substances
  • Mechanism of Action Immunostimulants; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Interleukin-15 receptor agonists; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Nov 2016 NKTR 255 is still in preclinical development for Cancer
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV, Infusion)
  • 18 Apr 2012 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top